Alvotech Welcomes Stelara Biosimilar Into Phase III Development

Joins Alvotech’s Biosimilar Humira Candidate

 
• By Dean Rudge

Alvotech has announced two studies running in parallel for the firm’s AVT04 ustekinumab biosimilar referencing Janssen’s $7.7bn Stelara treatment for autoimmune diseases, including a Phase III comparative study.

Spacecraft
Alvotech has launched two clinical trials • Source: Shutterstock

More from Biosimilars

More from Products